A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
Investigation of Pharmacokinetics Following Co-administration of Cagrilintide (NNC0174-0833) and Semaglutide Versus Separate Injections in Subjects With Overweight or Obesity
Sponsor: Novo Nordisk A/S
Listed as NCT04940078, this PHASE1 trial focuses on Obesity & Overweight and remains completed. Sponsored by Novo Nordisk A/S, it has been updated 11 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1
-
Nov 2025 — Jan 2026 [monthly]
Completed PHASE1
-
Sep 2024 — Nov 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE1
▶ Show 6 earlier versions
-
Mar 2023 — Mar 2024 [monthly]
Completed PHASE1
-
Apr 2022 — Mar 2023 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Mar 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Dec 2021 — Mar 2022 [monthly]
Recruiting PHASE1
-
Oct 2021 — Dec 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Jul 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .